Pregabalin abuse in France : a national cohort study

Study identification

• EU PAS number:
  EUPAS10298
• Study ID:
  28047
• Official title and acronym:
  Pregabalin abuse in France : a national cohort study
• DARWIN EU® study:
  No
• Study countries:
  France
• Study description:
  Pregabalin is a psychoactive drug indicated in neuropathic pain, generalized anxiety disorder and partial epilepsy. It modifies neuronal activity, binding α2δ1 presynaptic voltage-dependent calcic channel receptor, which is responsible for its psychotropic action. Neuropsychiatric adverse drug reactions, such as euphoria, have been described. Pregabalin abuse has been suggested in a few toxicological studies, pharmacovigilance studies, and small surveys among opioid users or treated by opiate maintenance drugs. Despite signals of abuse in some European countries, no data suggest a potential for pregabalin abuse in France, and no study has ever compare pregabalin abuse to other drug used in the same indication. Searching a possible pregabalin abuse seems all the more relevant as its consumption increases in France and in Europe. This study aims to investigate pregabalin abuse and its frequency in the French general population, in comparison with other drugs used in similar indications and to determine the factors associated with pregabalin abuse.
• Study status:
  Finalised

Research institutions and networks

Institutions

Pharmacologie En Population cohorteS biobanqueS (PEPSS), Hopitaux de Toulouse

France

Study timelines

Date when funding contract was signed

Planned:02/02/2015

Actual:02/02/2015

Study start date

Planned:06/04/2015

Actual:01/06/2015

Data analysis start date

Planned:04/05/2015

Actual:15/06/2015

Date of final study report

Planned:30/10/2015

Actual:24/12/2015

Sources of funding

Other

More details on funding

Toulouse University Hospital

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable